Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
Chimeric antigen receptor (CAR) therapies such as tisagenlecleucel, indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukemia (ALL), have been associated with striking treatment outcomes and overall survival. Yet, they are also associated with unique...
Main Authors: | Avis Harden, Dristhi Ragoonanan, Daryl Anildes-Gubman, David McCall, Kathleen Faltus, Sarah Featherston, Basirat Shoberu, Jerelyn R. Moffet, Demetrios Petropoulos, Sajad J. Khazal, Shehla Razvi, Kris M. Mahadeo, Priti Tewari |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01227/full |
Similar Items
-
EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study
by: Felix Korell, et al.
Published: (2022-04-01) -
Building safety into CAR-T therapy
by: Daniel T. Peters, et al.
Published: (2023-12-01) -
Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
by: Tim Lakomy, et al.
Published: (2023-02-01) -
A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome
by: Omar H. Butt, et al.
Published: (2023-02-01) -
Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
by: Castaneda-Puglianini O, et al.
Published: (2021-08-01)